Primary Article

Pharmacology of Kanamycin in the Newborn

Authors: CRAIG W. BEACHLER MD, MICHAEL E. SPEER MD, EDWARD O. MASON JR. PhD, MARTHA D. YOW MD

Abstract

ABSTRACTWe studied the pharmacologic effects of kanamycin in three groups of newborn infants: group 1—birth weight (BW) ≤ 2,000 gm, chronologic age (CA) < 7 days; group 2—BW > 2,000 gm, CA < 7 days; and group 3—BW > 2,000 gm, CA 7 to 28 days. The dose of kanamycin was 15 mg/kg/day, administered in two intramuscular doses. Serum kanamycin levels were measured 15 minutes before the dose and 1/2, 1, 6, and 8 hours after the dose. Infants in group 1 had a mean peak concentration of 18.7μg/ml, those in group 2, 19.6/μg/ml, and those in group 3, 15.6/μg/ml. The mean peak concentrations varied inversely with chronologic age but were not influenced by birth weight. Mean serum half-life varied inversely with birth weight, gestational age, and chronologic age. We recommend a standard dose of 15 mg/kg/day for newborn infants. Modification of this dose may be required for individual infants

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References